Investor Presentation Q1-Q3 2020
50
Investor presentation
First nine months of 2020
Novo Nordisk®
People with obesity are at an increased risk of developing severe
comorbidities that are life-threatening and costly for society
Only 2% of the 650 million people with obesity
Diabetes Increased risk of type 2 diabetes
are treated with prescription medication
Global healthcare cost related to obesity
expected to increase by 50% by 2025
CVD
Increased risk of CVD
Heart
failure
Increased risk of heart failure
650 million
people with
obesity
Sleep
apnoea
Increased severity of sleep apnoea
Visit the
doctor
Osteo-
arthritis
Increased risk of osteoarthritis
Discussion and
evaluation of
next steps Actively
managed¹
CVD: Cardiovascular disease; AOM: Anti-obesity medication, TRX SU Volume.
The figure illustrates some of the intervention points to treat obesity with prescription medication
1 Attempt to manage weight through lifestyle modification or surgery
22% of people with obesity are estimated to be treated with anti-obesity medication
Source: World Obesity Federation, 2017; IQVIA Xponent MAT, May 2020 and NSP MAT, May 2020; IQVIA MIDAS 2017
I
USD -0.8
trillion
USD -1.0
trillion
USD -1.2
trillion
2% treated²
2017
2020
2025View entire presentation